Christy L Willoughby1, Jérome Fleuriet2, Mark M Walton3, Michael J Mustari2, Linda K McLoon1. 1. Graduate Program in Neuroscience, University of Minnesota, Minneapolis, Minnesota, United States 2Department of Ophthalmology and Visual Neurosciences, University of Minnesota, Minneapolis, Minnesota, United States. 2. Washington National Primate Research Center, Seattle, Washington, United States 4Department of Ophthalmology, University of Washington, Seattle, Washington, United States. 3. Washington National Primate Research Center, Seattle, Washington, United States.
Abstract
PURPOSE: We evaluated promising new treatment options for strabismus. Neurotrophic factors have emerged as a potential treatment for oculomotor disorders because of diverse roles in signaling to muscles and motor neurons. Unilateral treatment with sustained release brain-derived neurotrophic factor (BDNF) to a single lateral rectus muscle in infant monkeys was performed to test the hypothesis that strabismus would develop in correlation with extraocular muscle (EOM) changes during the critical period for development of binocularity. METHODS: The lateral rectus muscles of one eye in two infant macaques were treated with sustained delivery of BDNF for 3 months. Eye alignment was assessed using standard photographic methods. Muscle specimens were analyzed to examine the effects of BDNF on the density, morphology, and size of neuromuscular junctions, as well as myofiber size. Counts were compared to age-matched controls. RESULTS: No change in eye alignment occurred with BDNF treatment. Compared to control muscle, neuromuscular junctions on myofibers expressing slow myosins had a larger area. Myofibers expressing slow myosin had larger diameters, and the percentage of myofibers expressing slow myosins increased in the proximal end of the muscle. Expression of BDNF was examined in control EOM, and observed to have strongest immunoreactivity outside the endplate zone. CONCLUSIONS: We hypothesize that the oculomotor system adapted to sustained BDNF treatment to preserve normal alignment. Our results suggest that BDNF treatment preferentially altered myofibers expressing slow myosins. This implicates BDNF signaling as influencing the slow twitch properties of EOM.
PURPOSE: We evaluated promising new treatment options for strabismus. Neurotrophic factors have emerged as a potential treatment for oculomotor disorders because of diverse roles in signaling to muscles and motor neurons. Unilateral treatment with sustained release brain-derived neurotrophic factor (BDNF) to a single lateral rectus muscle in infant monkeys was performed to test the hypothesis that strabismus would develop in correlation with extraocular muscle (EOM) changes during the critical period for development of binocularity. METHODS: The lateral rectus muscles of one eye in two infant macaques were treated with sustained delivery of BDNF for 3 months. Eye alignment was assessed using standard photographic methods. Muscle specimens were analyzed to examine the effects of BDNF on the density, morphology, and size of neuromuscular junctions, as well as myofiber size. Counts were compared to age-matched controls. RESULTS: No change in eye alignment occurred with BDNF treatment. Compared to control muscle, neuromuscular junctions on myofibers expressing slow myosins had a larger area. Myofibers expressing slow myosin had larger diameters, and the percentage of myofibers expressing slow myosins increased in the proximal end of the muscle. Expression of BDNF was examined in control EOM, and observed to have strongest immunoreactivity outside the endplate zone. CONCLUSIONS: We hypothesize that the oculomotor system adapted to sustained BDNF treatment to preserve normal alignment. Our results suggest that BDNF treatment preferentially altered myofibers expressing slow myosins. This implicates BDNF signaling as influencing the slow twitch properties of EOM.
Authors: María A Davis-López de Carrizosa; Camilo J Morado-Díaz; Sara Morcuende; Rosa R de la Cruz; Angel M Pastor Journal: J Neurosci Date: 2010-06-16 Impact factor: 6.167
Authors: Cheng-Yuan Feng; Grant W Hennig; Robert D Corrigan; Terence K Smith; Christopher S von Bartheld Journal: Exp Eye Res Date: 2012-05-03 Impact factor: 3.467
Authors: Mark M G Walton; Adam Pallus; Jérome Fleuriet; Michael J Mustari; Kristina Tarczy-Hornoch Journal: J Neurophysiol Date: 2017-04-12 Impact factor: 2.714
Authors: Andrea B Agarwal; Cheng-Yuan Feng; Amy L Altick; David R Quilici; Dan Wen; L Alan Johnson; Christopher S von Bartheld Journal: Invest Ophthalmol Vis Sci Date: 2016-10-01 Impact factor: 4.799
Authors: Andrea B Agarwal; Austin J Christensen; Cheng-Yuan Feng; Dan Wen; L Alan Johnson; Christopher S von Bartheld Journal: PeerJ Date: 2017-12-22 Impact factor: 2.984
Authors: Jérome Fleuriet; Christy L Willoughby; Rachel B Kueppers; Michael J Mustari; Linda K McLoon Journal: Sci Rep Date: 2020-07-17 Impact factor: 4.379
Authors: Linda K McLoon; Christy L Willoughby; Jill S Anderson; Erick D Bothun; David Stager; Joost Felius; Helena Lee; Irene Gottlob Journal: Invest Ophthalmol Vis Sci Date: 2016-04-01 Impact factor: 4.799